GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (FRA:3AC) » Definitions » Current Ratio

Actinogen Medical (FRA:3AC) Current Ratio : 5.42 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Actinogen Medical's current ratio for the quarter that ended in Dec. 2023 was 5.42.

Actinogen Medical has a current ratio of 5.42. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Actinogen Medical's Current Ratio or its related term are showing as below:

FRA:3AC' s Current Ratio Range Over the Past 10 Years
Min: 6.36   Med: 13.8   Max: 22.49
Current: 13.91

During the past 13 years, Actinogen Medical's highest Current Ratio was 22.49. The lowest was 6.36. And the median was 13.80.

FRA:3AC's Current Ratio is ranked better than
87.62% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs FRA:3AC: 13.91

Actinogen Medical Current Ratio Historical Data

The historical data trend for Actinogen Medical's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical Current Ratio Chart

Actinogen Medical Annual Data
Trend Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.97 19.95 13.79 7.04 13.91

Actinogen Medical Semi-Annual Data
Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.79 8.85 7.04 5.42 13.91

Competitive Comparison of Actinogen Medical's Current Ratio

For the Biotechnology subindustry, Actinogen Medical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's Current Ratio distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's Current Ratio falls into.



Actinogen Medical Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Actinogen Medical's Current Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Current Ratio (A: Jun. 2024 )=Total Current Assets (A: Jun. 2024 )/Total Current Liabilities (A: Jun. 2024 )
=11.644/0.837
=13.91

Actinogen Medical's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=7.276/1.342
=5.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actinogen Medical  (FRA:3AC) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Actinogen Medical Current Ratio Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical Business Description

Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Actinogen Medical Headlines

No Headlines